DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Lượt xem: 2
Danh sách Báo cáo các công ty nước ngoài
Tìm kiếm Báo cáo các công ty nước ngoài

Báo cáo thường niên năm 2022 của Passage Bio, Inc.

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Their portfolio spans pediatric and adult CNS indications, and they are currently advancing clinical programs in GM1 gangliosidosis and frontotemporal dementia and their preclinical pipeline … More , including programs in amyotrophic lateral sclerosis and Huntington’s disease. Based in Philadelphia, PA, their company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct their discovery and IND-enabling preclinical work. Through this collaboration, they have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that they then pair with their deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance their robust pipeline of optimized gene therapies. As they work with speed and tenacity, they are always mindful of patients who may be able to benefit from their therapies.

TÊN CÔNG TY / COMPANY
Passage Bio, Inc.

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)

MÃ CHỨNG KHOÁN / TICKER
PASG

KỲ BÁO CÁO
2022

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare

LƯU Ý

  • Xin vui lòng đợi một lát để Báo cáo được tải về, tùy thuộc vào dung lượng của Báo cáo mà thời gian có thể nhanh hoặc chậm.
  • Báo cáo chỉ cho phép xem từ Việt Nam.
NASDAQ_PASG_2022-DATA.KRESTON.VN

Có thể bạn quan tâm: